TrialBritish journal of haematology2016

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.

Takashi Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.